Literature DB >> 30064668

WHO preferred product characteristics for new vaccines against tuberculosis.

Lewis K Schrager1, Padmapriyadarsini Chandrasekaran2, Bernard H Fritzell3, Mark Hatherill4, Paul-Henri Lambert5, Helen McShane6, Nadia Tornieporth6, Johan Vekemans7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30064668     DOI： 10.1016/S1473-3099(18)30421-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  11 in total

Review 1.  The pathogenesis of post-primary tuberculosis. A game changer for vaccine development.

Authors:  Robert Hunter; Jeffrey Actor
Journal:  Tuberculosis (Edinb)       Date:  2019-04-26       Impact factor: 3.131

Review 2.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

Review 3.  Research and development of new tuberculosis vaccines: a review.

Authors:  Lewis K Schrager; Rebecca C Harris; Johan Vekemans
Journal:  F1000Res       Date:  2018-11-01

4.  Tuberculosis vaccines: Rising opportunities.

Authors:  Johan Vekemans; Katherine L O'Brien; Jeremy Farrar
Journal:  PLoS Med       Date:  2019-04-23       Impact factor: 11.069

5.  TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines.

Authors:  Federico Martinón-Torres; Xavier Bosch; Rino Rappuoli; Shamez Ladhani; Esther Redondo; Timo Vesikari; Adolfo García-Sastre; Irene Rivero-Calle; José Gómez-Rial; Antonio Salas; Carlos Martín; Adam Finn; Robb Butler
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

Review 6.  Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis.

Authors:  Chiara Bellini; Kata Horváti
Journal:  Cells       Date:  2020-12-15       Impact factor: 6.600

Review 7.  Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants.

Authors:  Ana Rita Franco; Francesco Peri
Journal:  Cells       Date:  2021-01-05       Impact factor: 6.600

8.  A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.

Authors:  Joshua S Woodworth; Helena Strand Clemmensen; Hannah Battey; Karin Dijkman; Thomas Lindenstrøm; Raquel Salvador Laureano; Randy Taplitz; Jeffrey Morgan; Claus Aagaard; Ida Rosenkrands; Cecilia S Lindestam Arlehamn; Peter Andersen; Rasmus Mortensen
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

Review 9.  Is mapping the BCG vaccine-induced immune responses the key to improving the efficacy against tuberculosis?

Authors:  R Kuan; K Muskat; B Peters; C S Lindestam Arlehamn
Journal:  J Intern Med       Date:  2020-11-19       Impact factor: 13.068

Review 10.  Clinical Development of New TB Vaccines: Recent Advances and Next Steps.

Authors:  Mark Hatherill; Richard G White; Thomas R Hawn
Journal:  Front Microbiol       Date:  2020-01-30       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.